Most clinical data integrity findings don’t start with fraud. They start with unreviewed audit trails, late source entries, and records that don’t match the EDC. For sponsors and CROs running trials in India, these gaps tend to surface at the worst possible moment: during a regulatory inspection or a sponsor audit.
GCP regulatory requirements on data integrity have also become more explicit. Pharmazone’s GCP services support sponsors, CROs and sites with audits, monitoring and compliance readiness across the clinical trial lifecycle. ICH E6(R3) (Source), adopted by ICH in January 2025, places data governance, risk-based quality management and computerized systems at the centre of trial oversight.
Here are six requirements sponsors often underestimate, and what it takes to close each gap.
Six GCP Regulatory Requirements Sponsors Often Miss
1. ALCOA+ Applies to Every Record, Not Just the EDC
ALCOA+ means data must be attributable, legible, contemporaneous, original and accurate, as well as complete, consistent, enduring and available. Teams often apply these principles carefully to the EDC and loosely to everything around it: paper source notes, ECG printouts, patient diaries and site emails. Inspectors trace data points from the CRF back to their origin, so one weak link can undermine the whole record. A source data location list for each protocol makes that chain clear.
2. Audit Trails Must Be Reviewed, Not Just Switched On
Most clinical systems log audit trails automatically. ICH E6(R3) expects appropriate procedures for reviewing trial data, audit trails and relevant metadata. Reviews should be planned, risk-based and clearly assigned to the responsible parties. The most frequent problem here is that there is no procedure for the audit trail review: who is going to review it, how frequently, and when it needs attention. Multiple modifications in one field, late entries, and mass updates done after working hours are among things that need to be checked.
3. Sponsor Oversight Cannot Be Delegated Away
Sponsors routinely outsource monitoring, data management, and safety reporting to CROs and vendors. Responsibility for data quality stays with the sponsor. Inspectors expect evidence of that oversight: documented vendor qualification, a clear oversight plan, and records showing the sponsor reviewed vendor performance and acted on issues.
4. Computerized Systems Need Fit-for-Purpose Validation
EDC, eTMF, IRT and ePRO systems all process trial data, and therefore each system must be appropriately validated. The validation certificate of a vendor is a baseline that does not replace the sponsor’s assessment of the system configuration and use. Uncontrolled reconciliation spreadsheets, unrevoked user accounts and logins after employee departure are typical issues.
5. Risk-based Quality Management Has to be Current
According to E6(R3), sponsors should assess critical-to-quality factors during study design and manage risks related to such factors. There are numerous cases when a risk management plan is developed once at the start of the trial and then not modified. Sponsors should be able to demonstrate how critical-to-quality risks are monitored, when predefined thresholds trigger escalation, and how emerging risks lead to documented corrective actions.
6. The Trial Master File Must Tell the Full Story
The TMF is how an inspector reconstructs a trial. Documents filed months late, missing versions of informed consent forms, and gaps in correspondence suggest weak control, even when the underlying work was done well. Contemporaneous filing and periodic completeness checks keep the TMF inspection-ready.
Know Where You Stand Before an Inspector Does
A practical way to test readiness is an independent, third-party review: a pre-inspection gap audit, a system audit or a focused TMF check. It shows how your trial data holds up against GCP regulatory requirements before a regulator reaches the same conclusions.
Pharmazone’s GCP compliance consulting supports sponsors, CROs and sites in identifying gaps, strengthening SOPs and preparing for inspections. Our teams also work across regulatory affairs and pharmacovigilance, so trial data is reviewed in the context of your wider compliance obligations.
To discuss an audit readiness review for your trial, contact our team.
